Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » Compliance Mentor » CMS Issues Final Rule on 340B Drug Program

    Compliance Mentor
    Compliance Mentor RSS FeedRSS

    compliance-mentor-static-reliasmedia

    Free Monthly News from the Award Winning Publisher of:

    • Hospital Access Management
    • Hospital Case Management
    • Hospital Employee Health
    • Hospital Infection Control
    • Hospital Peer Review
    • Healthcare Risk Management
    • Case Management Advisor
    • IRB Advisor
    • Medical Ethics Advisor
    • Same-Day Surgery

     

    CMS Issues Final Rule on 340B Drug Program

    November 16, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share
    By Robert B. Vogel, MD, JD

    Robert B. Vogel, MD, JD
    Retinal Ophthalmologist at Piedmont Eye Center, Lynchburg VA;
    Attorney, Overbey Hawkins & Wright, PLLS, Lynchburg, VA;
    Adjunct Professor, Humanities and Bioethics, Liberty University School of Medicine, Lynchburg, VA.

    The Centers for Medicare & Medicaid Services (CMS) finalized its rule concerning the amount that hospitals will be paid for delivering drugs to patients in the outpatient setting. The rule is promulgated pursuant to the Hospital Outpatient Prospective Payment System (OPPS) and the 340B drug program. The program ostensibly is being changed to lower the out-of-pocket drug costs of Medicare beneficiaries with copays for these Part B drugs. An estimated $320 billion will be saved by beneficiaries under this new rule.

    The 340B drug pricing program allows certain hospitals to obtain discounted prices on some outpatient drugs. This saves the hospitals money and was meant to allow eligible hospitals the ability to stretch government healthcare payments to allow for redistribution to other patients.

    Starting in January 2018, CMS will pay minus 22.5% rather than plus 6% of the average sales price (ASP) for these outpatient Part B drugs in the 340B program. The Medpac Report to Congress in 2015 estimated that the hospitals receive on average a 22.5% discount. The Medpac Report also points out that the 340B program has grown substantially over the past decade, in part due to increased eligibility criteria under the Affordable Care Act. Medicare paid the same amount for the drug to the 340B hospitals as the non-340B hospitals, despite the deep discount, making the 340B program very profitable.

    In a reversal from previous intentions, CMS decided in the final rule to roll the savings from the 340B program, which amounts to about $1.6 billion, into additional payments for both 340B and non-340B hospitals. Therefore, there will be a net gain to non-340B hospitals, which largely consist of for-profit hospitals. Certain children’s hospitals, cancer hospitals, and rural hospitals will be exempt from the 340B final rule.

    The American Hospital Association (AHA) and other stakeholders have announced proposed litigation over the 340B cuts. “We’re deeply disappointed in the Centers for Medicare & Medicaid Services’ recent decision to cut payments to hospitals participating in 340B that will put needed prescription drugs further out of reach, and dramatically threaten access to healthcare for many, including the uninsured, the elderly, those with chronic conditions and the disabled,” wrote AHA CEO Richard Pollack on the AHA blog.
     


    Live Training - blue

    Crosswalk to Compliance: CMS Hospital CoPs Series

    Our Hospital CoP series will give you a core understanding of the Hospital CoP requirements all employees must know. Our speaker will guide attendees through the entire CMS Hospital CoP manual and highlight proposed changes in survey memos, surveyor worksheets, and much more.

    Reserve Spot - Orange

    Save 15% on your subscription with promo code GOBBLE
    Promotion ends 11/30/2017


    newsletter-sponsors-relias_sr

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Compliance Mentor

    View PDF
    Compliance Mentor - November 2017
    November 1, 2017

    Table Of Contents

    INSYS Therapeutics Founder Charged With Racketeering Related to Fentanyl

    CMS Issues Final Rule on 340B Drug Program

    District Court Finds Dynamic Visions Home Health Violated the FCA

    Endoscopy Practice Settles Allegations of Medicare Fraud

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing